NOT KNOWN DETAILS ABOUT BRD4 INHIBITION BY ABBV-744 IN CANCER RESEARCH STUDIES

In Phase A, individuals will receive different doses and schedules of oral ABBV-744 pill to establish Risk-free dosing regimen. Additional contributors will probably be enrolled in the discovered monotherapy dosign routine. In Phase B, members will receive oral ruxolitinib and ABBV-744 are going to be supplied as "incorporate-on" therapy. In Sectio